|
Dec 5
|
Shareholders have faith in loss-making Ironwood Pharmaceuticals (NASDAQ:IRWD) as stock climbs 9.7% in past week, taking five-year gain to 2.3%
|
|
Nov 30
|
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
|
|
Oct 3
|
Ironwood Pharmaceuticals (IRWD): A Hidden Gem or a Potential Risk? An In-Depth Look at Its Valuation
|
|
Oct 1
|
Here's How to Lock in a Trade on a Promising Biopharma Name
|
|
Aug 9
|
Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises
|
|
Aug 9
|
Q2 2023 Ironwood Pharmaceuticals Inc Earnings Call
|
|
Aug 8
|
Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass Estimates
|
|
Aug 8
|
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
|